FOLFIRINOX化疗调节胰腺癌外周免疫景观:对联合治疗及早期反应预测的意义
研究纳入86例胰腺癌患者,于首个FOLFIRINOX周期前及后两周采集血样进行免疫细胞和蛋白质组分析,第四周期后影像学评估疗效。一个周期FOLFIRINOX降低肿瘤细胞相关通路、增强免疫激活通路,治疗前VEGFA和PRDX3高水平及一周期后FCRL3升高预测早期进展。
要点
- 一个周期FOLFIRINOX即可增强CD4+和CD8+T细胞活化、NK(T)增殖及抗原提呈细胞活化。
- 治疗前VEGFA和PRDX3高水平及一周期后FCRL3升高预测FOLFIRINOX早期进展。
- 进展患者B细胞和CD8+T细胞抑制标志物高,缓解患者CD4+和CD8+T细胞活化标志物高。
核心结论
- FOLFIRINOX具有免疫调节作用,为探索利用免疫系统治疗胰腺癌的免疫联合治疗临床试验提供了基础。
- 若干血浆蛋白有潜力作为循环预测生物标志物,用于早期预测胰腺癌患者对FOLFIRINOX的反应。
研究设计与样本
- 研究纳入86例胰腺癌患者,于首个FOLFIRINOX周期前及后两周采集血样,进行全面的免疫细胞和蛋白质组分析。
- 采用主成分分析和线性混合效应回归模型分析数据,FOLFIRINOX疗效于第四周期后经影像学评估。
主要发现
- 一个周期FOLFIRINOX降低肿瘤细胞相关通路,增强免疫激活相关通路,表现为促炎因子IL-18、IL-15和TNFRSF4升高。
- FOLFIRINOX促进CD4+和CD8+T细胞活化、NK(T)增殖及抗原提呈细胞活化。
- 治疗前VEGFA和PRDX3高水平及一个周期后FCRL3水平升高预测FOLFIRINOX治疗下早期进展。
- 进展患者B细胞和CD8+T细胞上抑制标志物水平高,而缓解患者CD4+和CD8+T细胞亚群上活化标志物水平高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: FOLFIRINOX chemotherapy has improved outcomes for pancreatic cancer patients, but poor long-term survival outcomes and high toxicity remain challenges. This study investigates the impact of FOLFIRINOX on plasma proteins and peripheral immune cells to guide immune-based combination therapies and, ideally, to identify a potential biomarker to predict early disease progression during FOLFIRINOX. METHODS: Blood samples were collected from 86 pancreatic cancer patients before and two weeks after the first FOLFIRINOX cycle and subjected to comprehensive immune cell and proteome profiling. Principal Component Analysis and Linear Mixed Effect Regression models were used for data analysis. FOLFIRINOX efficacy was radiologically evaluated after the fourth cycle. RESULTS: One cycle of FOLFIRINOX diminished tumour-cell-related pathways and enhanced pathways related to immune activation, illustrated by an increase in pro-inflammatory IL-18, IL-15, and TNFRSF4. Similarly, FOLFIRINOX promoted the activation of CD4 + and CD8 + T cells, the proliferation of NK(T), and the activation of antigen-presenting cells. Furthermore, high pre-treatment levels of VEGFA and PRDX3 and an elevation in FCRL3 levels after one cycle predicted early progression under FOLFIRINOX. Finally, patients with progressive disease exhibited high levels of inhibitory markers on B cells and CD8 + T cells, while responding patients exhibited high levels of activation markers on CD4 + and CD8 + T cell subsets. CONCLUSION: FOLFIRINOX has immunomodulatory effects, providing a foundation for clinical trials exploring immune-based combination therapies that harness the immune system to treat pancreatic cancer. In addition, several plasma proteins hold potential as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
引用
- van Eijck CWF, Strijk G, Vietsch EE, et al. FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction. Eur J Cancer. 2023. PMID: 37988843. doi:10.1016/j.ejca.2023.113440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。